TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22351300

Group type: EXPERIMENTAL
Intervention: Conventional bolus dose atropine (group A)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Rapidly incremental doses of atropine followed by infusion (group B)
Number of subjects: 156
Study: 20153039

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil
Number of subjects: 1006
Study: 17512638

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bicarbonate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 7
Study: 16371681

Group type: EXPERIMENTAL
Intervention: Group workshops and single one-on-one tutorials with parents, teachers, and providers about the evaluation and treatment of ADHD.
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 243
Study: 12143910

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 42
Study: 10453230

Group type: EXPERIMENTAL
Intervention: Oral co-amoxiclav (amoxycilline and clavulanic acid)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intramuscular ampicilline (control)
Number of subjects: 150
Study: 7628886

Group type: EXPERIMENTAL
Intervention: Circuit of seven exercises performed for 30 seconds each, repeated five times.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Circuit of seven exercises
Number of subjects: 20
Study: 2649120

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg twice daily increased to 10 mg twice daily after two weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 25
Study: 10943

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31140002

Group type: EXPERIMENTAL
Intervention: Laparoscopic drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endoscopic drainage
Number of subjects: 60
Study: 30907301

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel and aspirin)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Intravenous alteplase (0.9 mg/kg)
Number of subjects: 760
Study: 26815593

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 78
Study: 26078877

Group type: EXPERIMENTAL
Intervention: Intervention group (I) - Growing Leaps and Bounds program delivered by health care providers at 7-9 well-baby visits over 2 years.
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (C) - No specific intervention mentioned.
Number of subjects: 232
Study: 23524340

Group type: EXPERIMENTAL
Intervention: Group-based behavioral weight loss (4 months)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Migraine education (control)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 140
Study: 21474517

Group type: EXPERIMENTAL
Intervention: Specialist referral based on a probability of pre-eclampsia of at least 15% or an abnormal uterine artery Doppler waveform
Number of subjects: 3572

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3572
Study: 19296748

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 16703777

Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil cream with tape occlusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tape occlusion alone
Number of subjects: 40
Study: 15015668

Group type: EXPERIMENTAL
Intervention: Carmustine wafers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo wafers
Number of subjects: 24
Study: 11845814

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily for 12 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 9598884

Group type: EXPERIMENTAL
Intervention: Futuro wrist orthosis
Number of subjects: 40
Study: 7618651

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 2923081

Group type: EXPERIMENTAL
Intervention: Smokeless tobacco (ST) use
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nonusers (control group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Chronic ST use
Number of subjects: 58
Study: 320061

Group type: EXPERIMENTAL
Intervention: Diftalone (1,000 mg during the 1st week; 750 mg the 2nd week; 500 mg from the 3rd week on)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenylbutazone (400 mg during the 1st week; 300 mg the 2nd week; 200 mg from the 3rd week on)
Number of subjects: 30
Study: 31439579

Group type: EXPERIMENTAL
Intervention: Taselisib combined with tamoxifen (20mg once daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Taselisib (2 or 4 mg in an intermittent or continuous schedule)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Circulating tumor (ct)DNA studies
Number of subjects: 30
Study: 28927491

Group type: EXPERIMENTAL
Intervention: Hyaluronate plus CPAP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Saline solution plus CPAP
Number of subjects: 102

Group type: COMPARATOR
Intervention: CPAP-only
Number of subjects: 102
Study: 26410207

Group type: EXPERIMENTAL
Intervention: ERIGO training (30 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physiotherapist-assisted verticalization training (30 sessions)
Number of subjects: 20
Study: 24093352

Group type: EXPERIMENTAL
Intervention: Limited health literacy
Number of subjects: 226
Study: 21358807

Group type: EXPERIMENTAL
Intervention: Ion-exchange water softener plus usual eczema care
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual eczema care alone
Number of subjects: 336
Study: 19060764

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombin
Number of subjects: 0
Study: 17882839

Group type: EXPERIMENTAL
Intervention: Recombinant proinflammatory cytokines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic ligands for Toll‐like receptors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polycomponent vaccine containing antigens of opportunistic bacteria (Immunovac VP‐4)
Number of subjects: 0
Study: 15220700

Group type: EXPERIMENTAL
Intervention: Abacavir (n = 86)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Zidovudine (n = 32)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Discontinuation of d4T
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Treatment using abacavir or zidovudine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hyperlactatemia symptoms
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Serum transaminases normalization after d4T discontinuation
Number of subjects: 118
Study: 11348605

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 to 40 mg/day
Number of subjects: 6605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6605
Study: 9517940

Group type: EXPERIMENTAL
Intervention: ABCD (4 mg/kg of body weight daily) for up to 6 weeks
Number of subjects: 133
Study: 7822089

Group type: EXPERIMENTAL
Intervention: Steroids (40 mg of prednisone equivalent)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Steroids (40 mg of prednisone equivalent) + Cyclophosphamide (100 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Steroids (40 mg of prednisone equivalent) + Cyclosporine (5 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination treatments (Cyclophosphamide or Cyclosporine)
Number of subjects: 28
Study: 31153362

Group type: EXPERIMENTAL
Intervention: 4 week physiotherapy programme (6-8 sessions) of manual therapy, exercise and upper limb neural unloading tape
Number of subjects: 64

Group type: COMPARATOR
Intervention: Weekly phone advice (control)
Number of subjects: 64
Study: 28304350

Group type: EXPERIMENTAL
Intervention: Functional bread (low in starch, rich in fibers, 7 g/100 g, beta glucan/starch ratio of 7.6:100 g/g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular white bread (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional bread
Number of subjects: 0
Study: 25572800

Group type: EXPERIMENTAL
Intervention: ISTOP‐ADE system (interactive voice response system paired with pharmacist support)
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2200
Study: 23889689

Group type: EXPERIMENTAL
Intervention: Self-reported measures
Number of subjects: 301

Group type: COMPARATOR
Intervention: Professional teeth cleaning
Number of subjects: 301
Study: 22255101

Group type: EXPERIMENTAL
Intervention: Training with ramp platform perturbations at vestibular velocities (1, 2, 4 deg/sec; VESTIB n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clinical balance training (CBT n=3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Training with ramp platform perturbations at non-vestibular velocities (0.5, 8, 16 deg/sec; Non-VESTIB n=3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy control subjects (n=4)
Number of subjects: 12
Study: 19389331

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Bipolar disorder trials
Number of subjects: 77
Study: 16797329

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly, calcium 1 g daily, calcitriol 0.5 mug daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Historical control group (n=31)
Number of subjects: 59
Study: 14676153

Group type: EXPERIMENTAL
Intervention: Microdissection needle cautery at 8 W
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard monopolar electrocautery at 20 W
Number of subjects: 42
Study: 10845174

Group type: EXPERIMENTAL
Intervention: Stuartnatal Plus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Materna
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12799797

Group type: COMPARATOR
Intervention: Ultrasound at 0.3 W/cm2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasound at 0.7 W/cm2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasound at 1.0 W/cm2
Number of subjects: 30
Study: 8407397

Group type: EXPERIMENTAL
Intervention: Fast neutron radiotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional photon and/or electron radiotherapy
Number of subjects: 25
Study: 3006516

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.01-10 microM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Verapamil (0.01-10 microM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supplemental calcium
Number of subjects: 20
Study: 29023666

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA), choline, and uridine‐5‐monophosphate (UMP) supplementation for 2 years
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 40
Study: 26971109

Group type: EXPERIMENTAL
Intervention: Low-load exercises with partial vascular occlusion (PVO) at 30% of 1-RM for 6 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: High-load exercises without PVO at 70% of 1-RM for 6 weeks
Number of subjects: 34
Study: 24481031

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 130

Group type: COMPARATOR
Intervention: cTBNA
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: EBB
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: TBLB
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA + TBLB
Number of subjects: 130

Group type: COMPARATOR
Intervention: cTBNA + EBB + TBLB
Number of subjects: 130
Study: 22326505

Group type: EXPERIMENTAL
Intervention: Strawberry odor with strawberry and tomato images (Experiment 1)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: No odors with strawberry and tomato images (Experiment 2)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Strawberry odor with strawberry and tomato images (Experiment 2)
Number of subjects: 63
Study: 19897063

Group type: EXPERIMENTAL
Intervention: Raloxifene (group 1, n=20) continued for 96 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (group 2, n=20) after 96 weeks of raloxifene
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (group 3, n=14)
Number of subjects: 54
Study: 18414411

Group type: EXPERIMENTAL
Intervention: Docetaxel/gemcitabine
Number of subjects: 53
Study: 15598193

Group type: EXPERIMENTAL
Intervention: Women's program
Number of subjects: 122

Group type: COMPARATOR
Intervention: Mixed-gender community programs
Number of subjects: 122

Group type: COMPARATOR
Intervention: Mixed-gender hospital program
Number of subjects: 122
Study: 11846350

Group type: EXPERIMENTAL
Intervention: Distraction intervention using a developmentally appropriate electronic toy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 29
Study: 10022643

Group type: EXPERIMENTAL
Intervention: Total gastrectomy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jejunal S-shaped pouch after total gastrectomy
Number of subjects: 64
Study: 7790794

Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Amitriptyline therapy
Number of subjects: 150
Study: 1691355

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 371048

Group type: EXPERIMENTAL
Intervention: Kanamycin (1 gm four times a day) and erythromycin (750 mg three times a day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Kanamycin with placebo
Number of subjects: 77
Study: 31772611

Group type: EXPERIMENTAL
Intervention: Inulin (15 g for 21 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 15 g for 21 days)
Number of subjects: 38
Study: 28592166

Group type: EXPERIMENTAL
Intervention: Continuous bilateral thoracic paravertebral infusion of 0.5% lidocaine (1 mg.kg‐1.hr‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcutaneous infusion of lidocaine at the same rate through catheters inserted at the same locations
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 25361165

Group type: EXPERIMENTAL
Intervention: Fab/Fab
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: F(ab')2/F(ab')2
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: F(ab')2/placebo
Number of subjects: 121
Study: 24958605

Group type: EXPERIMENTAL
Intervention: RT‐then‐AT (8 weeks resistance training followed by 8 weeks aerobic exercise training)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CE‐then‐AT + RT (8 weeks of 'sham' training followed by 8 weeks concurrent aerobic and resistance training)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CE‐then‐AT (8 weeks 'sham' training followed by 8 weeks aerobic training)
Number of subjects: 75
Study: 21527575

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) doses of 30 mg, 50 mg, and 70 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19258602

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate and calcium‐phosphate cements
Number of subjects: 22

Group type: COMPARATOR
Intervention: Calcium‐phosphate cement
Number of subjects: 22
Study: 17718702

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no gabapentin)
Number of subjects: 14
Study: 15084807

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) 20 mg/kg/day (max. 500 mg) b.i.d. for 5 days
Number of subjects: 1952

Group type: COMPARATOR
Intervention: Penicillin V (PenV) 50,000 IU/kg (30 mg/kg) t.i.d. for 10 days
Number of subjects: 1952
Study: 11240535

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 256

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 256
Study: 9278836

Group type: COMPARATOR
Intervention: Low-flow anesthesia only (control, n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-flow anesthesia with additional reflective blankets (blanket, n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-flow anesthesia with active forced-air warming (forced-air, n = 10)
Number of subjects: 30
Study: 8315425

Group type: COMPARATOR
Intervention: Doxorubicin and Dacarbazine (AD)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Doxorubicin, Dacarbazine, and Ifosfamide (ADI)
Number of subjects: 340
Study: 3625594

Group type: EXPERIMENTAL
Intervention: Induced hyperventilation (Group FB: fast and deep breathing)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Slow breathing (Group SB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal breathing (Group NB)
Number of subjects: 48
Study: 30031747

Group type: EXPERIMENTAL
Intervention: Online-delivered walking intervention with access to the REACH website and personalized step goals.
Number of subjects: 171

Group type: COMPARATOR
Intervention: Comparison group received a paper diary and generic step goals.
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both groups received a pedometer.
Number of subjects: 171
Study: 29800179

Group type: EXPERIMENTAL
Intervention: High-frequency follow-up testing (computed tomography and carcinoembryonic antigen at 6, 12, 18, 24, and 36 months after surgery)
Number of subjects: 2509

Group type: COMPARATOR
Intervention: Low-frequency follow-up testing (computed tomography and carcinoembryonic antigen at 12 and 36 months after surgery)
Number of subjects: 2509
Study: 26068576

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Cisplatin with concomitant gefitinib (arm A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Cisplatin with sequential gefitinib (arm B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Gemcitabine plus Cisplatin alone (arm C)
Number of subjects: 105
Study: 24938526

Group type: EXPERIMENTAL
Intervention: HAART with Tenofovir/Emtricitabine plus Nevirapine
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: HAART with Tenofovir/Emtricitabine plus Lopinavir/Ritonavir
Number of subjects: 625

Group type: COMPARATOR
Intervention: Non-SCR group
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: SCR group
Number of subjects: 625
Study: 22190027

Group type: EXPERIMENTAL
Intervention: Exercise-induced dehydration with no diuretic (DN)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exercise-induced dehydration plus diuretic (DD; furosemide, 40 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Euhydration (EU)
Number of subjects: 25
Study: 20704666

Group type: EXPERIMENTAL
Intervention: Transforaminal injection of steroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transforaminal injection of local anesthetic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transforaminal injection of saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular injection of steroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular injection of saline
Number of subjects: 0
Study: 17430436

Group type: EXPERIMENTAL
Intervention: Individually adjustable saddle-type chairs with wheels and desks with comfort curve and arm support
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional workstations
Number of subjects: 97
Study: 15773400

Group type: EXPERIMENTAL
Intervention: Inactivated poliomyelitis vaccine (IPV) 'Imovax Polio'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral vaccine (following IPV)
Number of subjects: 0
Study: 12200465

Group type: EXPERIMENTAL
Intervention: Fetal erythroblast numbers and cell-free DNA concentrations in maternal blood samples
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pathological placental conditions
Number of subjects: 0
Study: 10417577

Group type: EXPERIMENTAL
Intervention: Botox injections to the glabella, forehead or lateral canthal regions
Number of subjects: 40

Group type: COMPARATOR
Intervention: No additional treatment (control group)
Number of subjects: 40
Study: 7732714

Group type: EXPERIMENTAL
Intervention: Lifestyle changes program (low-fat vegetarian diet, stress management techniques, aerobic exercises, group support meetings)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pravastatin 20 mg/day (lipid-lowering drug)
Number of subjects: 40
Study: 2277377

Group type: EXPERIMENTAL
Intervention: Cefmetazole (1 g intramuscularly preoperatively)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cefonicid (1 g intramuscularly preoperatively)
Number of subjects: 81
Study: 6153260

Group type: EXPERIMENTAL
Intervention: Zoster immune globulin (ZIG)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Normal serum globulin (NSG)
Number of subjects: 97
Study: 31905354

Group type: EXPERIMENTAL
Intervention: Teleleader
Number of subjects: 22

Group type: COMPARATOR
Intervention: Teleconsultant
Number of subjects: 22
Study: 31729982

Group type: EXPERIMENTAL
Intervention: Idelalisib + bendamustine/rituximab
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo + bendamustine/rituximab
Number of subjects: 416
Study: 28249075

Group type: EXPERIMENTAL
Intervention: Group 2 (diagnostic labels provided)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group 1 (no information)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ADSD severity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Additional information about ADSD
Number of subjects: 20
Study: 26226029

Group type: EXPERIMENTAL
Intervention: PHAX
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 24
Study: 24167992

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound
Number of subjects: 224

Group type: COMPARATOR
Intervention: Low-temperature plasm radiofrequency
Number of subjects: 224
Study: 20393478

Group type: EXPERIMENTAL
Intervention: B‐NCPAP
Number of subjects: 18

Group type: COMPARATOR
Intervention: V‐NCPAP
Number of subjects: 18
Study: 19589241

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atenolol (50 mg/day)
Number of subjects: 60
Study: 17557045

Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux (GER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empirical treatment for extraesophageal manifestations of GER
Number of subjects: 0